Literature DB >> 1382646

FK 506 and autoimmune disease: perspective and prospects.

A W Thomson1, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1382646      PMCID： PMC2967358          DOI： 10.3109/08916939209148473

Source DB:  PubMed          Journal:  Autoimmunity        ISSN： 0891-6934            Impact factor:   2.815


× No keyword cloud information.
  59 in total

1.  Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings.

Authors: 
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Pharmacokinetics of FK 506: preclinical and clinical studies.

Authors:  R Venkataramanan; A Jain; E Cadoff; V Warty; K Iwasaki; K Nagase; A Krajack; O Imventarza; S Todo; J J Fung
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  FK 506: a new therapeutic agent for severe recalcitrant psoriasis.

Authors:  K Abu-Elmagd; D Van Thiel; B V Jegasothy; C D Ackerman; S Todo; J J Fung; A W Thomson; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

4.  Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.

Authors:  R Venkataramanan; A Jain; V W Warty; K Abu-Elmagd; H Furakawa; O Imventarza; J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

5.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

6.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

7.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

8.  Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat.

Authors:  M Mochizuki; H Kawashima
Journal:  Autoimmunity       Date:  1990       Impact factor: 2.815

9.  Antigen presentation and HLA-DR expression by FK-506-treated human monocytes.

Authors:  J Woo; D J Propper; A W Thomson
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

10.  Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats.

Authors:  H Kawashima; Y Fujino; M Mochizuki
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-08       Impact factor: 4.799
View more
  6 in total

Review 1.  Diabetes tolerogenic vaccines targeting antigen-specific inflammation.

Authors:  Shuang Geng; Huiyuan Zhang; Xian Zhou; Yue He; Xiaoqian Zhang; Xiaoping Xie; Chaofan Li; Zhonghuai He; Qingling Yu; Yiwei Zhong; Douglas B Lowrie; Guoxing Zheng; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  New immunosuppressive drugs: mechanistic insights and potential therapeutic advances.

Authors:  A W Thomson; T E Starzl
Journal:  Immunol Rev       Date:  1993-12       Impact factor: 12.988

3.  Immunophilins, Refsum disease, and lupus nephritis: the peroxisomal enzyme phytanoyl-COA alpha-hydroxylase is a new FKBP-associated protein.

Authors:  B Chambraud; C Radanyi; J H Camonis; K Rajkowski; M Schumacher; E E Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

4.  Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production.

Authors:  K Tamura; J Woo; N Murase; G Carrieri; M A Nalesnik; A W Thomson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

5.  Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures.

Authors:  A W Thomson; J Woo; G Z Yao; S Todo; T E Starzl; A Zeevi
Journal:  Transpl Immunol       Date:  1993       Impact factor: 1.708

6.  FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice.

Authors:  F Furukawa; S Imamura; M Takigawa
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.